Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Dermatomyositis Treatment Market Size, Value And Growth Trajectory Through 2030
The market for dermatomyositis treatments has experienced robust expansion over recent years. It is projected to increase from $0.91 billion in 2025 to $0.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. Historically, this growth has been influenced by heightened autoimmune disease recognition, the availability of corticosteroids, the expansion of rheumatology clinics, the adoption of hospital-based immunotherapy, and the progress in supportive care development.
The dermatomyositis treatment market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $1.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This anticipated growth during the forecast period is fueled by several factors, including the expansion of biologic pipelines, advances in precision immunology, early autoimmune screening initiatives, the development of personalized treatment protocols, and the increasing establishment of specialty clinics. Key developments shaping the market in this timeframe encompass a greater adoption of biologic therapies, an increasing dependence on immunosuppressive medications, the broadening of combination treatment strategies, an uptick in the use of long-term physical therapy, and enhancements in early diagnosis and disease monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Dermatomyositis Treatment Market Growth Drivers: What’s Behind The Acceleration?
The escalating occurrence of autoimmune disorders is projected to fuel the expansion of the dermatomyositis treatment market in the future. Autoimmune diseases are conditions in which the body’s immune system mistakenly attacks its own healthy cells and tissues. The increase in the prevalence of autoimmune diseases stems from advancements in diagnostic techniques, greater public awareness, and environmental factors, leading to higher detection rates and a rise in reported cases. Dermatomyositis treatment plays a role in addressing the growing prevalence of autoimmune diseases by offering targeted therapies that diminish harmful immune responses and improve the quality of life for affected individuals. For instance, in February 2024, according to the Autoimmune Institute, a US-based nonprofit organization, autoimmune diseases collectively impact 5–10% of the population in industrialized nations. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the dermatomyositis treatment market.
Dermatomyositis Treatment Market Segment Trends And Revenue Contributors
The dermatomyositis treatment market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatments, Immunosuppressants, Corticosteroids, Biologics, Physical Therapy
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Demographics: Age Group, Gender
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Pharmacological Treatments: Antimalarials, Antiviral Agents, Muscle Relaxants, Analgesics
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
4) By Biologics: Rituximab, Intravenous Immunoglobulin (IVIG), Tocilizumab, Abatacept
5) By Physical Therapy: Stretching Exercises, Strength Training, Aerobic Conditioning, Occupational Therapy
Dermatomyositis Treatment Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the dermatomyositis treatment market are concentrating on developing innovative solutions, such as selective complement-pathway inhibitors, to address the increasing need for more targeted and safer therapies that bypass the extensive immune suppression of conventional treatments. These selective complement-pathway inhibitors work by specifically blocking components of the complement cascade responsible for driving inflammation in dermatomyositis, thereby offering a more precise mechanism of action than traditional immunosuppressive agents, which can broadly diminish immune function. For instance, in February 2025, NovelMed Therapeutics Inc., a US-based clinical-stage biotech company, secured clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II trial for Ruxoprubart (NM8074). This compound is a highly selective blocker of the alternative complement pathway, specifically targeting Factor Bb. Ruxoprubart has demonstrated its capacity to modulate immune response by reducing critical inflammatory drivers while preserving essential immune functions such as opsonization and bacterial clearance, potentially minimizing risk compared to broader complement blockers. This novel therapy’s efficacy and safety in dermatomyositis are currently under evaluation.
Dermatomyositis Treatment Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., Corbus Pharmaceuticals Holdings Inc.
View The Full Dermatomyositis Treatment Market Report:
Dermatomyositis Treatment Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the dermatomyositis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomyositis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
